Charles W Schindler1, Eric B Thorndike1, Masaki Suzuki2, Kenner C Rice2, Michael H Baumann3. 1. Preclinical Pharmacology Section, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD. 2. Drug Design and Synthesis Section, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD. 3. Designer Drug Research Unit, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD.
Abstract
BACKGROUND AND PURPOSE: 3,4-Methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with stimulatory cardiovascular effects that can lead to serious medical complications. Here, we examined the pharmacological mechanisms underlying these cardiovascular actions of MDPV in conscious rats. EXPERIMENTAL APPROACH: Male Sprague-Dawley rats had telemetry transmitters surgically implanted for the measurement of BP and heart rate (HR). On test days, rats were placed individually in standard isolation cubicles. Following drug treatment, cardiovascular parameters were monitored for 3 h sessions. KEY RESULTS: Racemic MDPV (0.3-3.0 mg·kg-1 ) increased BP and HR in a dose-dependent manner. The S(+) enantiomer (0.3-3.0 mg·kg-1 ) of MDPV produced similar effects, while the R(-) enantiomer (0.3-3.0 mg·kg-1 ) had no effects. Neither of the hydroxylated phase I metabolites of MDPV altered cardiovascular parameters significantly from baseline. Pretreatment with the ganglionic blocker chlorisondamine (1 and 3 mg·kg-1 ) antagonized the increases in BP and HR produced by 1 mg·kg-1 MDPV. The α1 -adrenoceptor antagonist prazosin (0.3 mg·kg-1 ) attenuated the increase in BP following MDPV, while the β-adrenoceptor antagonists propranolol (1 mg·kg-1 ) and atenolol (1 and 3 mg·kg-1 ) attenuated the HR increases. CONCLUSIONS AND IMPLICATIONS: The S(+) enantiomer appeared to mediate the cardiovascular effects of MDPV, while the metabolites of MDPV did not alter BP or HR significantly; MDPV increased BP and HR through activation of central sympathetic outflow. Mixed-action α/β-adrenoceptor antagonists may be useful as treatments in counteracting the adverse cardiovascular effects of MDPV. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND AND PURPOSE:3,4-Methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with stimulatory cardiovascular effects that can lead to serious medical complications. Here, we examined the pharmacological mechanisms underlying these cardiovascular actions of MDPV in conscious rats. EXPERIMENTAL APPROACH: Male Sprague-Dawley rats had telemetry transmitters surgically implanted for the measurement of BP and heart rate (HR). On test days, rats were placed individually in standard isolation cubicles. Following drug treatment, cardiovascular parameters were monitored for 3 h sessions. KEY RESULTS: Racemic MDPV (0.3-3.0 mg·kg-1 ) increased BP and HR in a dose-dependent manner. The S(+) enantiomer (0.3-3.0 mg·kg-1 ) of MDPV produced similar effects, while the R(-) enantiomer (0.3-3.0 mg·kg-1 ) had no effects. Neither of the hydroxylated phase I metabolites of MDPV altered cardiovascular parameters significantly from baseline. Pretreatment with the ganglionic blocker chlorisondamine (1 and 3 mg·kg-1 ) antagonized the increases in BP and HR produced by 1 mg·kg-1 MDPV. The α1 -adrenoceptor antagonist prazosin (0.3 mg·kg-1 ) attenuated the increase in BP following MDPV, while the β-adrenoceptor antagonists propranolol (1 mg·kg-1 ) and atenolol (1 and 3 mg·kg-1 ) attenuated the HR increases. CONCLUSIONS AND IMPLICATIONS: The S(+) enantiomer appeared to mediate the cardiovascular effects of MDPV, while the metabolites of MDPV did not alter BP or HR significantly; MDPV increased BP and HR through activation of central sympathetic outflow. Mixed-action α/β-adrenoceptor antagonists may be useful as treatments in counteracting the adverse cardiovascular effects of MDPV. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Charles W Schindler; Eric B Thorndike; Kenner C Rice; John S Partilla; Michael H Baumann Journal: J Pharmacol Exp Ther Date: 2019-03-21 Impact factor: 4.030
Authors: Charles W Schindler; Benjamin R Gramling; Zuzana Justinova; Eric B Thorndike; Michael H Baumann Journal: Drug Alcohol Depend Date: 2017-08-18 Impact factor: 4.492
Authors: Dino Luethi; Karolina E Kolaczynska; Melanie Walter; Masaki Suzuki; Kenner C Rice; Bruce E Blough; Marius C Hoener; Michael H Baumann; Matthias E Liechti Journal: J Psychopharmacol Date: 2019-04-30 Impact factor: 4.153
Authors: Helene L Philogene-Khalid; Callum Hicks; Allen B Reitz; Lee-Yuan Liu-Chen; Scott M Rawls Journal: Drug Alcohol Depend Date: 2017-06-13 Impact factor: 4.492
Authors: Jose Luiz Costa; Kelly Francisco Cunha; Rafael Lanaro; Ricardo Leal Cunha; Donna Walther; Michael H Baumann Journal: Drug Test Anal Date: 2018-10-21 Impact factor: 3.345
Authors: Samantha J McClenahan; Michael D Hambuchen; Christy M Simecka; Melinda G Gunnell; Michael D Berquist; S Michael Owens Journal: Drug Alcohol Depend Date: 2019-01-04 Impact factor: 4.492